JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients. (2018)

First Author: Gallipoli P
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.34092

Publication URI: https://www.repository.cam.ac.uk/handle/1810/286785

Type: Journal Article/Review